Neurological Biomarker Market Scope
Neurological biomarkers assist in inspecting and analyzing neurological diseases since it provides a strong approach for understanding the properties of the neurological disease with numerous applications in randomized clinical trials analytic epidemiology, prognosis, and screening & diagnosis. Over the past few decades, unhealthier and unfavorable lifestyles have led to an increasing prevalence of neurological disorders across the global population. Careful assessment of the validity of biomarkers is required with respect to the stage of the disease. Causes of variability in the measurement of biomarkers range from the individual to the laboratory.
The market study is being classified by Type (Imaging Biomarkers, Metabolomics Biomarkers, Proteomic Biomarkers and Genomics Biomarkers), by Application (Spinal Muscular Atrophy (SMA), Multiple Sclerosis, Depression, Schizophrenia, Huntingtonís Disease, Parkinsonís Disease and Alzheimerís Disease) and major geographies with country level break-up. According to AMA, the Global Neurological Biomarker market is expected to see growth rate of 9.91% and may see market size of USD7806.2 Million by 2024.
The Players having a strong hold in the market are Abbott Laboratories, Myriad RBM, Proteome Sciences, Thermo Fisher Scientific, and, Athena Diagnostics. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Neurological Biomarker market throughout the predicted period.
Abbott Laboratories (United States), Myriad RBM Inc. (United States), Proteome Sciences (United Kingdom), Thermo Fisher Scientific (United States), Athena Diagnostics (India), Immunarray Pvt Ltd (Israel), Quanterix Corporation (United States), Diagenic ASA (Norway), Psynova Neurotech Ltd (United Kingdom) and Bio-Rad Laboratories, Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Qiagen (Germany), AbaStar MDx, Inc. (United States), Acumen Pharmaceuticals, Inc. (United States) and Abiant, Inc. (United States).
AdvanceMarketAnalytics has segmented the market of Global Neurological Biomarker market by Type, Application and Region. On the basis of Type, Genomics Biomarkers are dominating the market in the year 2018
On the basis of geography, the market of Neurological Biomarker has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North Amercia region held largest market share in the year 2018. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Neurological Biomarker market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Leaders and their expansionary development strategies
On June 17, 2019, the global humanitarian organization CARE, the healthcare company Abbott and its foundation the Abbott Fund has announced a three-year partnership valued at 1 million USD which will assist in screening, diagnosing, preventing and managing and managing of noncommunicable diseases (NCDs) for people who remain displaced two years after armed conflict in Philippines.
The FDAís Center for Devices and Radiological Health (CDRH) conducts research to support science-based and transparent decisions and minimize assumptions and subjectivity in the device review process. FDA scientists advance regulatory science by developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of medical devices.
- Upsurging Technological Advancements in Molecular Biology and Laboratory Technology
- Rising Prevalence of Alzheimers and Parkinsons Diseases
- Assists in Inspecting and Analysing Neurological Diseases
- Increasing Neurological Disorders across the Global Population
- Increasing Preferences Towards Customized and Personalised Medicines Across the Globe
- Robustly Growing Healthcare Infrastructure from Emerging Economies
- Lack of Awareness about the Neurological Biomarker from Underdeveloped Economies
- Comparatively Expensive Solutions and Prone to Laboratory Errors might Stagnate the Demand
- A dearth of Skilled Neurologists across the Globe
Key Target AudienceNeurological Biomarker Manufacturers, Neurological Biomarker Distributors and Traders, Neurological Biomarker Upstream and Downstream Buyers, Health Care Industry Associations, Research and Development Organizations, Government Regulators, Financial Institutes and Non-Profit Organizations and Others
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase